Description
CJC-1295 + Ipamorelin is a two-peptide research blend in one vial: CJC-1295 without DAC (Modified GRF 1-29) 5 mg and ipamorelin 5 mg, 10 mg in total. It pairs a short-acting GHRH analog with a selective ghrelin-receptor (GHS-R1a) agonist, the two receptor pathways that control pulsatile growth hormone release.
CJC-1295 + Ipamorelin Research Details
Research on this pairing looks at how GHRH-receptor and ghrelin-receptor signaling work together at the pituitary, including pulsatile GH release, receptor selectivity and downstream IGF-1 axis endpoints. This blend uses the short-acting no-DAC form of CJC-1295.
Independent lab report not yet posted for this product (tested lots are listed on our Lab Results page)
CJC-1295 no DAC (Mod GRF 1-29) 5 mg · Ipamorelin 5 mg
Lyophilized powder
Laboratory research only
Research Background
Key OneBio research contexts include GHRH and GHS-R receptor assays, secretagogue combination studies, pituitary signaling and GH/IGF-1 axis research.
Specifications
| Compound | CJC-1295 + Ipamorelin |
| Vial Size | 10 mg (blend) |
| CAS Number | Blend (see components) |
| Molecular Formula | Blend |
| Molecular Weight | Blend |
| Identifier | Mod GRF(1-29) 863288-34-0 · Ipamorelin 170851-70-4 |
| Storage | -4°F long-term; 35-46°F short-term refrigerated; keep sealed, dry and away from light |
Quality Verification
Where an independent third-party lab report is available for a lot, it is posted on our Lab Results page and matched to the lot number on the vial. Each report covers only the lot that was tested. Contact us with your lot number to ask about documentation for your vial.
Handling
Handle only in a qualified laboratory under your institution’s validated protocols. Keep cold-chain handling and avoid repeated freeze-thaw cycles.

Reviews
There are no reviews yet.